Advice

following a full submission considered under the ultra-orphan and end of life process:

avelumab (Bavencio®) is accepted for use within NHSScotland.

Indication under review: As monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC).

An uncontrolled phase II study demonstrated that treatment with avelumab for patients with mMCC who had received prior chemotherapy produced improvements in objective response rate, duration of response and overall survival compared with historical chemotherapy controls from a retrospective cohort study.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Download full details353KB (PDF)

Download

Medicine details

Medicine name:
avelumab (Bavencio)
SMC ID:
1315/18
Indication:
indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC)
Pharmaceutical company
Merck Serono Europe Limited / Pfizer Limited
BNF chapter
Submission type
Full submission
Status
Accepted
Date advice published:
07 May 2018